Quantcast
Last updated on April 17, 2014 at 12:46 EDT

Latest Graft-versus-host disease Stories

2011-12-12 13:23:11

Technique expands scarce resources used for cord blood transplant procedure A new method to boost the number of immune cells in umbilical cord blood prior to cord blood transplants for cancer patients appears to lead to a quicker rebuilding of a new immune system in the patient's body than with a conventional cord blood transplant procedure, according to new research from the Perelman School of Medicine at the University of Pennsylvania that will be presented today at the 53rd American...

2011-12-12 12:05:31

New research findings in 25 presentations Researchers from Seidman Cancer Center at University Hospitals (UH) Case Medical Center and Case Western Reserve University School of Medicine presented new research findings in 25 presentations this weekend at the 53rd Annual Meeting of the American Society of Hematology (ASH) at the San Diego Convention Center. "The breadth and depth of this innovative cancer research presented at ASH is truly outstanding," says Stan Gerson, MD, Director of...

2011-12-12 06:00:00

PRINCETON, N.J., Dec. 12, 2011 /PRNewswire/ -- Soligenix, Inc. (Soligenix or the Company) (OTC BB: SNGX), a development stage biopharmaceutical company, announced the publication of results from its investigator-initiated Phase 2 "proof-of-concept" exploratory clinical trial of orBec® for the prevention of acute Graft-versus-Host disease (GVHD) in patients undergoing myeloablative conditioning regimens with initiation of dosing prior to hematopoietic cell...

2011-12-10 18:00:00

CLEVELAND, Dec. 10, 2011 /PRNewswire/ -- Researchers from Seidman Cancer Center at University Hospitals (UH) Case Medical Center and Case Western Reserve University School of Medicine presented new research findings in 25 presentations this weekend at the 53rd Annual Meeting of the American Society of Hematology (ASH) at the San Diego Convention Center. "The breadth and depth of this innovative cancer research presented at ASH is truly outstanding," says Stan Gerson, MD, Director...

2011-12-10 13:00:00

SAN DIEGO, Dec. 10, 2011 /PRNewswire-USNewswire/ -- Hematopoietic cell transplantation (HCT), the transplantation of blood-forming stem cells from the bone marrow, peripheral blood, or umbilical cord blood, is the primary option for treatment for many patients who suffer from various hematologic disorders, including blood cancers, sickle cell disease, bone marrow deficiencies, bleeding disorders, and autoimmune disorders. Research investigating breakthroughs in hematopoietic cell...

2011-12-06 07:00:00

RARITAN, N.J., Dec. 6, 2011 /PRNewswire/ -- Therakos, Inc., a pioneer in the innovative treatment of extracorporeal photopheresis (ECP) for immune modulation therapy, today announced that the first patient has been enrolled in its Phase IIb clinical study evaluating the use of the company's photopheresis technology in the treatment of patients with moderate-to-severe chronic Graft-versus-Host Disease (GvHD). An estimated 15,000 new patients worldwide are diagnosed every year...

2011-12-01 13:10:16

Study has implications for treatment of other immune-mediated disorders In a study that seems to pivot on a paradox, scientists at Dana-Farber Cancer Institute have used an immune system stimulant as an immune system suppressor to treat a common, often debilitating side effect of donor stem cell transplantation in cancer patients. The effect, in some cases, was profound. The phase I study, published in the Dec. 1 issue of the New England Journal of Medicine, involved allogeneic (donor)...

2011-11-14 06:00:00

PRINCETON, N.J., Nov. 14, 2011 /PRNewswire/ -- Soligenix, Inc. (OTCBB: SNGX) (Soligenix or the Company), a development stage biopharmaceutical company, announced today its financial results for the third quarter of 2011. Soligenix's revenues for the third quarter of 2011 were approximately $5,796,000 as compared to $861,000 for the third quarter of 2010. The increase in revenues was a result of a $5 million license fee from Sigma-Tau Pharmaceuticals, Inc. (Sigma-Tau) in connection with...

Cord Blood Treatment Receives FDA Approval
2011-11-11 09:59:21

US drug regulators for the first time have approved a therapy using cells of human blood from the placenta and the umbilical cord to treat cancer or blood-forming disorders, reports ABC News. The US Food and Drug Administration (FDA) on Thursday officially licensed HEMACORD (Hematopoietic Progenitor Cells-Cord, HPC-C) for “use in unrelated donor hematopoietic progenitor cell transplantation procedures“¦ in patients with disorders affecting the hematopoietic system that...

2011-11-10 15:06:00

SILVER SPRING, Md., Nov. 10, 2011 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved HEMACORD, the first licensed hematopoietic progenitor cells-cord (HPC-C) cell therapy. (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO) HEMACORD is indicated for use in hematopoietic stem cell transplantation procedures in patients with disorders affecting the hematopoietic (blood forming) system. For example, cord blood transplants have been used to treat...